Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

(OP: RLFTY )

5.976 UNCHANGED
Streaming Delayed Price Updated: 11:58 AM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about RLFTY

< Previous 1 2 3 4 Next >
Relief Therapeutics Announces Full Year 2022 Financial Results and Provides Corporate Update
Via ACCESSWIRE
Relief Therapeutics Announces Executive Leadership Team Change
Via ACCESSWIRE
Relief Therapeutics Holding SA to Hold Extraordinary General Meeting of Shareholders
Via ACCESSWIRE
Relief Therapeutics Appoints World-Renowned Gene Therapy Pioneer Guangping Gao, Ph.D. as Chair of Scientific Advisory Board
Via ACCESSWIRE
Relief Therapeutics Announces Survey Results Identifying Preferred Urea Cycle Disorder Treatment Attributes Presented by Collaboration Partner at SIMD 2023
Via ACCESSWIRE
Relief Therapeutics Announces Availability of New PKU GOLIKE BARs in Europe
Via ACCESSWIRE
Relief Announces U.S. Launch of PKU GOLIKE
Via ACCESSWIRE
Relief Announces Exclusive Distributor for PKU GOLIKE in the U.S.
Via ACCESSWIRE
Relief Therapeutics to Present Pre-Clinical Evidence for Improved Amino Acid Utilization with PKU GOLIKE at the Society for Inherited Metabolic Disorders 44th Annual Meeting
Via ACCESSWIRE
Relief Therapeutics Provides Update From Collaboration Partner on OLPRUVA
Via ACCESSWIRE
Relief Therapeutics Recognizes Rare Disease Day and Announces U.S. Availability of New PKU GOLIKE Bars
Via ACCESSWIRE
Relief Therapeutics Announces Enrollment of First Three Patients in Proof-of-Concept Clinical Trial of RLF-TD011 for the Treatment of Epidermolysis Bullosa
Via ACCESSWIRE
Relief Therapeutics Provides an Update on its Financing Strategy
Via ACCESSWIRE
Relief Therapeutics Appoints David McCullough as Head of U.S. Market Access
Via ACCESSWIRE
Relief Therapeutics Announces IRB Approval of Investigator-Initiated Trial Evaluating RLF-TD011 as an Adjunctive Treatment for Cutaneous T-Cell Lymphom
Via ACCESSWIRE
Relief Therapeutics Files Amendment No. 2 to its Registration Statement on Form F-1 with the U.S. Securities and Exchange Commission
Via ACCESSWIRE
Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Close of Definitive Settlement Agreements
Via ACCESSWIRE
Relief Therapeutics to Participate in January Investor Meetings
Via ACCESSWIRE
RELIEF THERAPEUTICS Holding SA and NRx Pharmaceuticals, Inc. Extend Their Stay of Pending Litigation to Provide Additional Time for The Parties to Finalize Their Settlement
Via ACCESSWIRE
Relief Therapeutics Files Amendment No. 2 to its Form F-6 Registration Statement with the U.S. Securities and Exchange Commission
Via ACCESSWIRE
Relief Therapeutics Announces Promotion of Paolo Galfetti to Chief Operating Officer
Via ACCESSWIRE
Relief Therapeutics Announces IRB Approval and Initiation of an Investigator Initiated Trial of Nexodyn for Epidermolysis Bullosa at Ann & Robert H. Lurie Children's Hospital of Chicago
Via ACCESSWIRE
Relief Reports Half-Year 2022 Results and Provides Corporate Update
Via ACCESSWIRE
Relief Therapeutics to Participate in the 22nd Annual Biotech in Europe Forum
Via ACCESSWIRE
Relief Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
Via ACCESSWIRE
Relief Therapeutics Files Registration Statement on form F-1 with the U.S. Securities and Exchange Commission
Via ACCESSWIRE
Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Tentative Settlement of Pending Litigation
Via ACCESSWIRE
Relief Therapeutics Announces Promising Initial Stability Data on a New Formulation of RLF-100(R) (Aviptadil)
Via ACCESSWIRE
Relief Therapeutics Announces Effectiveness of Registration Statement on Form 20-F
Via ACCESSWIRE
Relief Therapeutics Announces Effectiveness of Registration Statement on Form 20-F
GENEVA, SWITZERLAND / ACCESSWIRE / July 21, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF, OTCQB:RLFTF, RLFTY) (" Relief ") announced today that the U.S. Securities and Exchange Commission (" SEC ")... 
From Relief Therapeutics Holdings AG
Via AccessWire
Topics Regulatory Compliance
Exposures Legal Regulatory
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.